The expression of high levels of IL-1β was associated with lower overall survival and progression-free survival in patients with non-small cell lung cancer (NSCLC) and pancreatic cancer who were administered chemotherapy [38,39]. This evidence concerns the gene IL1B and familial pancreatic carcinoma.